Loading...
•
Dec 31, 2022
Vir Q4 2022 Earnings Report
Vir Biotechnology reported results for the fourth quarter and full year 2022, highlighting the delivery of sotrovimab, initiation of Phase 2 trials, and new data on hepatitis B.
Key Takeaways
Vir Biotechnology reported Q4 2022 revenues of $49.4 million and a net loss of $101.6 million. The company delivered approximately 63,000 sotrovimab doses and recognized $26.4 million of grant revenue in connection with the BARDA agreement.
Vir Biotechnology delivered sotrovimab to millions of patients worldwide.
The company initiated two critical Phase 2 trials in influenza and hepatitis D.
Important new data on hepatitis B was reported.
Vir secured a multi-year government contract with the potential for up to $1 billion.
Revenue by Segment
Forward Guidance
Vir Biotechnology anticipates data from multiple trials in 2023 regarding Hepatitis B, Hepatitis D and Influenza programs.
Positive Outlook
- Data expected from multiple trials in 2023 for Hepatitis B program.
- Initial data expected from Phase 2 SOLSTICE trial evaluating VIR-2218 and VIR-3434 for Hepatitis D in the second half of 2023.
- Initial data expected from Phase 2 PENINSULA trial evaluating VIR-2482 for Influenza A in mid-2023.
- Initial data expected from Phase 1b prophylaxis trial evaluating the safety of VIR-2482 in adults aged 65 and older receiving a flu vaccine in mid-2023.
- Safety and immunology data from the highest dose cohort 3 of the proof-of-concept Phase 1 trial of VIR-1111 for HIV are anticipated in the first half of 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...